Trial
NCT02117479
Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)
Phase IIITERMINATEDEFFICACY/FUTILITYConfidence: MEDIUM
Sponsor
Incyte Corporation
Collaborators
—
Condition
Pancreatic Cancer
Intervention
Ruxolitinib
Why stopped
The study was terminated early based on the results of the planned interim analysis.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2019-03-26